Navigation Links
Concentric Named Professional Agency of Record for Discovery Labs' SURFAXIN(R)
Date:9/3/2008

NEW YORK, Sept. 3 /PRNewswire/ -- Concentric Pharma Advertising, one of the fastest growing marketing agencies in the healthcare field, has been named agency of record by Discovery Labs for SURFAXIN(R) (lucinactant), an investigational drug being reviewed by the Food and Drug Administration for the treatment of respiratory distress syndrome (RDS) in newborns.

"We selected Concentric for this assignment because the company's strategic insight and creative vision best captured the essence of the SURFAXIN brand," said John Wilson, vice president of sales and marketing at Discovery, adding that the agency's in-depth knowledge of neonatology and acute RDS in premature infants also played a significant part in the decision.

The full-service U.S. assignment will include a wide range of activities, including corporate and product branding, positioning, and the creation of support materials geared to neonatologists, neonatal intensive care unit (NICU) nurses, respiratory therapists, hospital pharmacists, and, potentially, parents of newborns. The agency's account team will be led by Ed Mutch, account supervisor. Blake Benner, director of marketing at Discovery Labs, will manage the account on the client side.

Discovery Labs, headquartered in Warrington, Pa., is a biotechnology company developing novel surfactant replacement therapies (SRTs) with potential for application across the continuum of respiratory diseases, initially focusing on RDS in premature infants.

About Concentric

Concentric Pharma Advertising, an independent healthcare advertising and marketing firm established in 2002, is one of the fastest growing agencies in the healthcare field, enjoying double-digit revenue growth for the fourth year in a row. In the past year alone, the agency won 10 new assignments, launched a new division, expanded its senior management team, and won several awards in prestigious U.S. and global ad competitions.

Concentric offers a wide range of fully integrated marketing services, including professional and DTC advertising, corporate and product branding, sales force education, sales promotion, strategic and tactical planning, digital media, managed markets planning, formulary access programs, relationship marketing, and a full range of patient and consumer education programs. Clients include Alcon Labs, Bayer HealthCare, Cobalt Laboratories, Coria Laboratories, Discovery Labs, Mitsubishi Pharma USA, Neuromed, Pfizer and Wyeth.

Concentric is located at 71 West 23rd St, 9th floor, New York, NY 10010, but will soon be moving into spacious new quarters in lower Manhattan. To learn more, visit http://www.concentric-rx.com , call 212-633-9700, or email info@concentric-rx.com.

CONTACT: Julie Laitin (212) 286-2424 Cynthia Amorese (908) 665-8072

Email: jlaitin@julielaitin.com Email: camorese@comcast.net


'/>"/>
SOURCE Concentric Pharma Advertising
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Concentric Medical(R) Announces Co-Marketing Agreement With InTouch Health(R) to Advance Acute Ischemic Stroke Care
2. Concentric Wins Full-Service Professional Assignment From Biopharm Innovator Neuromed
3. Stoppert Named as President and CEO at Breakthrough Renewable Technology Firm Segetis, Inc
4. Baxa Corporation Named to Inc. 5000 for Second Consecutive Year as One of the Fastest-Growing Private Companies in the US
5. IDIS Opens New American Office in Response to Industrys Growing Need for Pre-Launch Named Patient Programs
6. Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area
7. Bill Pollock, President and CEO of Pharmagistics Group, Named to PharmaVOICE List of 100 Most Inspiring and Influential Leaders in the Life Sciences
8. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
9. William F. Prendergast Named One of the Top IP Lawyers in Nanotechnology
10. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
11. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Jan. 23, 2017  Alkahest Inc. ("Alkahest"), a ... neurodegenerative diseases and other age-related conditions, announced today ... as Chief Medical Officer. In this role, Dr. ... activities at Alkahest and serve on the Executive ... served as Executive Director at Dynavax, where he ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/20/2017)... ... January 20, 2017 , ... The two newest companies ... options for patients. Vironika, a spin out from The Wistar Institute, and Sanguis, launched ... space at 3624 Market Street. , Vironika is developing a treatment for a ...
(Date:1/19/2017)... Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their ... Cancer ... reach $15,737 million by 2022 from $6,521 in 2015, growing at ... Omic technologies segment accounted for more than half of the revenue ...
Breaking Biology Technology:
(Date:12/15/2016)... HILLS, Mich. , Dec. 15, 2016  There ... unlocking car doors or starting the engine. Continental will ... in Las Vegas . Through the ... (Passive Start and Entry) and biometric elements, the international ... field of vehicle personalization and authentication. "The ...
(Date:12/8/2016)... 8, 2016 Market Research Future published a half cooked ... Mobile Biometric Security and Service Market is expected to grow over ... Market Highlights: ... Mobile Biometric Security and Service ... increasing need of authentication and security from unwanted cyber threats. The ...
(Date:12/7/2016)... AVIV, Israel , December 7, 2016 ... with the expansion of its patent portfolio, which grew to over 40 ... , , ... by its recently filed patent entitled " System, Device, and ... covers technology that enables device makers to forego costly hardware components needed ...
Breaking Biology News(10 mins):